<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33056982</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-4889</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Oct</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell death &amp; disease</Title>
          <ISOAbbreviation>Cell Death Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1.</ArticleTitle>
        <Pagination>
          <StartPage>858</StartPage>
          <MedlinePgn>858</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">858</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-020-03047-y</ELocationID>
        <Abstract>
          <AbstractText>Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, has greatly affected clinical outcomes in non-small cell lung cancer (NSCLC) patients. The long noncoding RNAs (lncRNAs) are known to regulate tumorigenesis and cancer progression, but their contributions to NSCLC gefitinib resistance remain poorly understood. In this study, by analyzing the differentially expressed lncRNAs in gefitinib-resistant cells and gefitinib-sensitive cells in the National Institute of Health GEO dataset, we found that lncRNA CASC9 expression was upregulated, and this was also verified in resistant tissues. Gain and loss of function studies showed that CASC9 inhibition restored gefitinib sensitivity both in vitro and in vivo, whereas CASC9 overexpression promoted gefitinib resistance. Mechanistically, CASC9 repressed the tumor suppressor DUSP1 by recruiting histone methyltransferase EZH2, thereby increasing the resistance to gefitinib. Furthermore, ectopic expression of DUSP1 increased gefitinib sensitivity by inactivating the ERK pathway. Our results highlight the essential role of CASC9 in gefitinib resistance, suggesting that the CASC9/EZH2/DUSP1 axis might be a novel target for overcoming EGFR-TKI resistance in NSCLC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Zhenyao</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Medical Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Qinnan</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Medical Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Zhixiang</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Medical Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Jingyao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Medical Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Wenyan</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Medical Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lei</LastName>
            <ForeName>Tianyao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Medical Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Jiali</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Medical Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pu</LastName>
            <ForeName>Jiaze</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Medical Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China. chen_xin4945@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhaoxia</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Medical Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China. zhaoxiawang66@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cell Death Dis</MedlineTA>
        <NlmUniqueID>101524092</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000622084">long noncoding RNA CASC9, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.48</RegistryNumber>
          <NameOfSubstance UI="C517019">DUSP1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.48</RegistryNumber>
          <NameOfSubstance UI="D054638">Dual Specificity Phosphatase 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S65743JHBS</RegistryNumber>
          <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054638" MajorTopicYN="N">Dual Specificity Phosphatase 1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063185" MajorTopicYN="N">Epigenetic Repression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062085" MajorTopicYN="N">RNA, Long Noncoding</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>17</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33056982</ArticleId>
        <ArticleId IdType="pmc">PMC7560854</ArticleId>
        <ArticleId IdType="doi">10.1038/s41419-020-03047-y</ArticleId>
        <ArticleId IdType="pii">10.1038/s41419-020-03047-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21590</ArticleId>
            <ArticleId IdType="pubmed">31912902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct. Target Ther. 2019;4:61. doi: 10.1038/s41392-019-0099-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-019-0099-9</ArticleId>
            <ArticleId IdType="pmc">PMC6914774</ArticleId>
            <ArticleId IdType="pubmed">31871778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat. Rev. Clin. Oncol. 2018;15:694–708. doi: 10.1038/s41571-018-0081-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-018-0081-4</ArticleId>
            <ArticleId IdType="pubmed">30108370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Remon J, et al.  Advanced-stage non-small cell lung cancer: advances in thoracic oncology 2018. J. Thorac. Oncol. 2019;14:1134–1155. doi: 10.1016/j.jtho.2019.03.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2019.03.022</ArticleId>
            <ArticleId IdType="pubmed">31002952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Z, Lei W, Hu HB, Zhang H, Zhu Y. H19 promotes non-small-cell lung cancer (NSCLC) development through STAT3 signaling via sponging miR-17. J. Cell Physiol. 2018;233:6768–6776. doi: 10.1002/jcp.26530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.26530</ArticleId>
            <ArticleId IdType="pubmed">29693721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian B, et al.  LncRNA H19 serves as a ceRNA and participates in non-small cell lung cancer development by regulating microRNA-107. Eur. Rev. Med Pharm. Sci. 2018;22:5946–5953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30280776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fazi B, et al.  The lncRNA H19 positively affects the tumorigenic properties of glioblastoma cells and contributes to NKD1 repression through the recruitment of EZH2 on its promoter. Oncotarget. 2018;9:15512–15525. doi: 10.18632/oncotarget.24496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.24496</ArticleId>
            <ArticleId IdType="pmc">PMC5884644</ArticleId>
            <ArticleId IdType="pubmed">29643989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Z, et al.  Long non-coding RNA SNHG20 promotes non-small cell lung cancer cell proliferation and migration by epigenetically silencing of P21 expression. Cell Death Dis. 2017;8:e3092. doi: 10.1038/cddis.2017.484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2017.484</ArticleId>
            <ArticleId IdType="pmc">PMC5682652</ArticleId>
            <ArticleId IdType="pubmed">28981099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29:452–463. doi: 10.1016/j.ccell.2016.03.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2016.03.010</ArticleId>
            <ArticleId IdType="pmc">PMC4831138</ArticleId>
            <ArticleId IdType="pubmed">27070700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, et al.  Long noncoding RNA LINC01234 functions as a competing endogenous RNA to regulate CBFB expression by sponging miR-204-5p in gastric cancer. Clin. Cancer Res. 2018;24:2002–2014. doi: 10.1158/1078-0432.CCR-17-2376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-2376</ArticleId>
            <ArticleId IdType="pubmed">29386218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen, Z. et al. Integrative analysis of NSCLC identifies LINC01234 as an oncogenic lncRNA that interacts with HNRNPA2B1 and regulates miR-106b biogenesis. Mol. Ther., 10.1016/j.ymthe.2020.03.010 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7264428</ArticleId>
            <ArticleId IdType="pubmed">32246902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Z, et al.  Up-regulated LINC01234 promotes non-small-cell lung cancer cell metastasis by activating VAV3 and repressing BTG2 expression. J. Hematol. Oncol. 2020;13:7. doi: 10.1186/s13045-019-0842-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-019-0842-2</ArticleId>
            <ArticleId IdType="pmc">PMC6972004</ArticleId>
            <ArticleId IdType="pubmed">31959200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, et al.  Long noncoding RNA LINC01116 contributes to gefitinib resistance in non-small cell lung cancer through regulating IFI44. Mol. Ther. Nucleic Acids. 2020;19:218–227. doi: 10.1016/j.omtn.2019.10.039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.omtn.2019.10.039</ArticleId>
            <ArticleId IdType="pmc">PMC6920314</ArticleId>
            <ArticleId IdType="pubmed">31841994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, et al.  lncRNA UCA1 promotes gefitinib resistance as a ceRNA to target FOSL2 by sponging miR-143 in non-small cell lung cancer. Mol. Ther. Nucleic Acids. 2020;19:643–653. doi: 10.1016/j.omtn.2019.10.047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.omtn.2019.10.047</ArticleId>
            <ArticleId IdType="pmc">PMC6965519</ArticleId>
            <ArticleId IdType="pubmed">31951852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin X, Liu X, Zhang Z, Guan Y. lncRNA CCAT1 acts as a microRNA-218 sponge to increase gefitinib resistance in NSCLC by targeting HOXA1. Mol. Ther. Nucleic Acids. 2020;19:1266–1275. doi: 10.1016/j.omtn.2020.01.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.omtn.2020.01.006</ArticleId>
            <ArticleId IdType="pmc">PMC7029377</ArticleId>
            <ArticleId IdType="pubmed">32084702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maik-Rachline, G., Hacohen-Lev-Ran, A. &amp; Seger, R. Nuclear ERK: mechanism of translocation, substrates, and role in cancer. Int. J. Mol. Sci. 20, 10.3390/ijms20051194 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6429060</ArticleId>
            <ArticleId IdType="pubmed">30857244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, et al.  PLK1 and HOTAIR accelerate proteasomal degradation of SUZ12 and ZNF198 during hepatitis B virus-induced liver carcinogenesis. Cancer Res. 2015;75:2363–2374. doi: 10.1158/0008-5472.CAN-14-2928.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-2928</ArticleId>
            <ArticleId IdType="pmc">PMC4452430</ArticleId>
            <ArticleId IdType="pubmed">25855382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhan J, et al.  HOXB13 networking with ABCG1/EZH2/Slug mediates metastasis and confers resistance to cisplatin in lung adenocarcinoma patients. Theranostics. 2019;9:2084–2099. doi: 10.7150/thno.29463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.29463</ArticleId>
            <ArticleId IdType="pmc">PMC6485289</ArticleId>
            <ArticleId IdType="pubmed">31037158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fillmore CM, et al.  EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature. 2015;520:239–242. doi: 10.1038/nature14122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14122</ArticleId>
            <ArticleId IdType="pmc">PMC4393352</ArticleId>
            <ArticleId IdType="pubmed">25629630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balak MN, et al.  Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 2006;12:6494–6501. doi: 10.1158/1078-0432.CCR-06-1570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-06-1570</ArticleId>
            <ArticleId IdType="pubmed">17085664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engelman JA, et al.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–1043. doi: 10.1126/science.1141478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1141478</ArticleId>
            <ArticleId IdType="pubmed">17463250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16:e165–e172. doi: 10.1016/S1470-2045(14)71180-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(14)71180-5</ArticleId>
            <ArticleId IdType="pmc">PMC4470698</ArticleId>
            <ArticleId IdType="pubmed">25846096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu HA, et al.  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 2013;19:2240–2247. doi: 10.1158/1078-0432.CCR-12-2246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-2246</ArticleId>
            <ArticleId IdType="pmc">PMC3630270</ArticleId>
            <ArticleId IdType="pubmed">23470965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol. Cancer. 2018;17:38. doi: 10.1186/s12943-018-0777-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-018-0777-1</ArticleId>
            <ArticleId IdType="pmc">PMC5817870</ArticleId>
            <ArticleId IdType="pubmed">29455650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Li Y, Gao H. Long noncoding RNA CASC9 promotes the proliferation and metastasis of papillary thyroid cancer via sponging miR-488-3p. Cancer Med. 2020;9:1830–1841. doi: 10.1002/cam4.2839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.2839</ArticleId>
            <ArticleId IdType="pmc">PMC7050070</ArticleId>
            <ArticleId IdType="pubmed">31943867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding Y, Li X, Zhang Y, Zhang J. Long non-coding RNA cancer susceptibility 9 (CASC9) up-regulates the expression of ERBB2 by inhibiting miR-193a-5p in colorectal cancer. Cancer Manag. Res. 2020;12:1281–1292. doi: 10.2147/CMAR.S234620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CMAR.S234620</ArticleId>
            <ArticleId IdType="pmc">PMC7039100</ArticleId>
            <ArticleId IdType="pubmed">32110102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang J, Chen W, Meng XL. LncRNA CASC9 suppressed the apoptosis of gastric cancer cells through regulating BMI1. Pathol. Oncol. Res. 2020;26:475–482. doi: 10.1007/s12253-019-00703-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12253-019-00703-3</ArticleId>
            <ArticleId IdType="pubmed">31642035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, Chen D, Liu H, Yang K. Increased expression of lncRNA CASC9 promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the AKT/mTOR pathway in oral squamous cell carcinoma. Cell Death Dis. 2019;10:41. doi: 10.1038/s41419-018-1280-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-018-1280-8</ArticleId>
            <ArticleId IdType="pmc">PMC6381212</ArticleId>
            <ArticleId IdType="pubmed">30674868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, et al.  The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC. Cell Cycle. 2018;17:1772–1783. doi: 10.1080/15384101.2018.1496745.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15384101.2018.1496745</ArticleId>
            <ArticleId IdType="pmc">PMC6133316</ArticleId>
            <ArticleId IdType="pubmed">30010468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, et al.  LINC00665 induces acquired resistance to gefitinib through recruiting EZH2 and activating PI3K/AKT pathway in NSCLC. Mol. Ther. Nucleic Acids. 2019;16:155–161. doi: 10.1016/j.omtn.2019.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.omtn.2019.02.010</ArticleId>
            <ArticleId IdType="pmc">PMC6424064</ArticleId>
            <ArticleId IdType="pubmed">30889481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, et al.  Reciprocal interaction of HOTAIR and SP1 together enhance the ability of Xiaoji decoction and gefitinib to inhibit EP4 expression. J. Ethnopharmacol. 2019;237:128–140. doi: 10.1016/j.jep.2019.03.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jep.2019.03.027</ArticleId>
            <ArticleId IdType="pubmed">30910577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J, et al.  LncRNA SNHG15 regulates EGFR-TKI acquired resistance in lung adenocarcinoma through sponging miR-451 to upregulate MDR-1. Cell Death Dis. 2020;11:525. doi: 10.1038/s41419-020-2683-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-2683-x</ArticleId>
            <ArticleId IdType="pmc">PMC7354989</ArticleId>
            <ArticleId IdType="pubmed">32655137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han B, et al.  ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma. Theranostics. 2020;10:3351–3365. doi: 10.7150/thno.41219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.41219</ArticleId>
            <ArticleId IdType="pmc">PMC7053195</ArticleId>
            <ArticleId IdType="pubmed">32194873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun J, et al.  miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer. Oncogene. 2019;38:564–580. doi: 10.1038/s41388-018-0459-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-018-0459-x</ArticleId>
            <ArticleId IdType="pmc">PMC7474467</ArticleId>
            <ArticleId IdType="pubmed">30166592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang S, et al.  H3K27me3 induces multidrug resistance in small cell lung cancer by affecting HOXA1 DNA methylation via regulation of the lncRNA HOTAIR. Ann. Transl. Med. 2018;6:440. doi: 10.21037/atm.2018.10.21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/atm.2018.10.21</ArticleId>
            <ArticleId IdType="pmc">PMC6281536</ArticleId>
            <ArticleId IdType="pubmed">30596070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katona BW, Liu Y, Ma A, Jin J, Hua X. EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells. Cancer Biol. Ther. 2014;15:1677–1687. doi: 10.4161/15384047.2014.972776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/15384047.2014.972776</ArticleId>
            <ArticleId IdType="pmc">PMC4622469</ArticleId>
            <ArticleId IdType="pubmed">25535899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arrizabalaga O, et al.  High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response. Oncogenesis. 2017;6:401. doi: 10.1038/s41389-017-0003-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41389-017-0003-9</ArticleId>
            <ArticleId IdType="pmc">PMC5865544</ArticleId>
            <ArticleId IdType="pubmed">29284798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo, F. et al. Deubiquitinating enzyme USP33 restrains docetaxel-induced apoptosis via stabilising the phosphatase DUSP1 in prostate cancer. Cell Death Differ., 10.1038/s41418-019-0473-8 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7244590</ArticleId>
            <ArticleId IdType="pubmed">31857702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan S, et al.  Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924. Cell Death Dis. 2019;10:883. doi: 10.1038/s41419-019-2123-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-019-2123-y</ArticleId>
            <ArticleId IdType="pmc">PMC6877515</ArticleId>
            <ArticleId IdType="pubmed">31767833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu DW, Chen CY, Chu CL, Lee H. Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability. Oncogene. 2016;35:621–630. doi: 10.1038/onc.2015.120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2015.120</ArticleId>
            <ArticleId IdType="pubmed">25915848</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
